CD47 and neoplasm: Such insufficient expression disparity on target and nontarget sites results in an “on‐target” effect (known as the “on‐target off‐tumor” effect in antitumor treatments[2]) with target‐mediated toxicities, restraining the otherwise promising clinical application of antibody‐related therapies.[3] CD47, as a highlighted target for anticancer immune checkpoint blockade therapies,[4] has been challenged by on‐target erythrotoxicity, platelet toxicity, and T‐cell toxicity due to unwanted target recognition and blocking.